Cargando…

Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status

BACKGROUND: Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilsmaier, Theresa, Heidegger, Helene Hildegard, Schröder, Lennard, Trapp, Elisabeth, zehni, Alaleh Zati, Rack, Brigitte, Janni, Wolfgang, Mahner, Sven, Weissenbacher, Tobias, Jeschke, Udo, Mumm, Jan-Niclas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854415/
https://www.ncbi.nlm.nih.gov/pubmed/32929618
http://dx.doi.org/10.1007/s00404-020-05793-y
_version_ 1783646083589603328
author Vilsmaier, Theresa
Heidegger, Helene Hildegard
Schröder, Lennard
Trapp, Elisabeth
zehni, Alaleh Zati
Rack, Brigitte
Janni, Wolfgang
Mahner, Sven
Weissenbacher, Tobias
Jeschke, Udo
Mumm, Jan-Niclas
author_facet Vilsmaier, Theresa
Heidegger, Helene Hildegard
Schröder, Lennard
Trapp, Elisabeth
zehni, Alaleh Zati
Rack, Brigitte
Janni, Wolfgang
Mahner, Sven
Weissenbacher, Tobias
Jeschke, Udo
Mumm, Jan-Niclas
author_sort Vilsmaier, Theresa
collection PubMed
description BACKGROUND: Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for breast cancer patients. METHODS: Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 patients’ sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera for Interleukin 15 (IL-15) and eotaxin. RESULTS: Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly correlate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS and DFS, showed statistically significant elevated eotaxin values. CONCLUSION: These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies.
format Online
Article
Text
id pubmed-7854415
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78544152021-02-08 Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status Vilsmaier, Theresa Heidegger, Helene Hildegard Schröder, Lennard Trapp, Elisabeth zehni, Alaleh Zati Rack, Brigitte Janni, Wolfgang Mahner, Sven Weissenbacher, Tobias Jeschke, Udo Mumm, Jan-Niclas Arch Gynecol Obstet Gynecologic Oncology BACKGROUND: Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for breast cancer patients. METHODS: Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 patients’ sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera for Interleukin 15 (IL-15) and eotaxin. RESULTS: Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly correlate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS and DFS, showed statistically significant elevated eotaxin values. CONCLUSION: These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies. Springer Berlin Heidelberg 2020-09-14 2021 /pmc/articles/PMC7854415/ /pubmed/32929618 http://dx.doi.org/10.1007/s00404-020-05793-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Gynecologic Oncology
Vilsmaier, Theresa
Heidegger, Helene Hildegard
Schröder, Lennard
Trapp, Elisabeth
zehni, Alaleh Zati
Rack, Brigitte
Janni, Wolfgang
Mahner, Sven
Weissenbacher, Tobias
Jeschke, Udo
Mumm, Jan-Niclas
Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
title Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
title_full Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
title_fullStr Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
title_full_unstemmed Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
title_short Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status
title_sort interleukin 15 and eotaxin correlate with the outcome of breast cancer patients vice versa independent of ctc status
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854415/
https://www.ncbi.nlm.nih.gov/pubmed/32929618
http://dx.doi.org/10.1007/s00404-020-05793-y
work_keys_str_mv AT vilsmaiertheresa interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT heideggerhelenehildegard interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT schroderlennard interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT trappelisabeth interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT zehnialalehzati interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT rackbrigitte interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT janniwolfgang interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT mahnersven interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT weissenbachertobias interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT jeschkeudo interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT mummjanniclas interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus
AT interleukin15andeotaxincorrelatewiththeoutcomeofbreastcancerpatientsviceversaindependentofctcstatus